Background
==========

Cervical cancer is the most frequent malignancy in Indian women, and is responsible for substantial morbidity and mortality worldwide \[[@B1]\]. Persistent infection with high-risk human papillomavirus (HR-HPV), most notably types 16 and 18 is an essential prerequisite for the development of cervical cancer \[[@B2]\]. During malignant progression, the HPV integrates into the host cell genome resulting in a loss of expression of the viral E2 gene and over-expression of the two early viral oncogenes E6 and E7, the products of which interfere with the tumor suppressor proteins p53 and Rb respectively. E6 binds and induces ubiquitin mediated degradation of p53 while E7 inactivate pRb leading to dysregulated cell growth \[[@B3]\].

The constitutive expression of HR-HPV E6 and E7 oncogene is mainly dependent on the availability of host cell transcription factors. Activator protein-1(AP-1) which is a heterodimer of a group of structurally and functionally related members of the Jun proteins (c-Jun, JunB, JunD) and Fos proteins (c-Fos, FosB, Fra-1 and Fra-2) found to be constitutively active in cervical cancer. Mutational inactivation of AP-1 consensus sequence within the binding sites of the HR-HPV upstream regulatory region (URR) revealed a complete loss of transcriptional activity of the E6/E7 promoter indicating a key role of AP-1 in HPV-mediated carcinogenesis \[[@B4]\]. Interestingly, AP-1 independently has also been shown to develop carcinogenesis in a variety of tissues \[[@B5]\]. Additionally, studies by our group demonstrated a significant overexpression of constitutively active AP-1 family members in cervical precancer and cancer tissues \[[@B6]\].

The most important risk factor in this cancer is the presence of human papillomavirus (HPV) infection. Conventional therapies like removal of lesions through cryo, laser therapy, excisional surgery, or topical application of formulations of podophyllotoxin, trichloroacetic acid and salicylic acid or 5-fluorouracil, including direct injections of interferon into the lesions may help eliminate the lesions or warts but none of them eradicates the virus. Consequently, recurrence of the lesions, as well as transmission of the virus remains a very significant problem. Since HR-HPV E6 and E7 are the two transforming proteins constantly expressed in transformed cells, they represent ideal targets for development of anti-HPV therapeutics \[[@B7]\]. Antiviral approach against transcriptional inactivation of HPV using herbal derivatives that show minimal or no systemic toxicity could be a promising option to control HPV infection particularly in an early stage of cervical carcinogenesis.

Berberine (5, 6-dihydro-9, 10-dimethoxybenzo\[g\]-1, 3-benzodioxole5,6-aquinolizum) (Figure [1](#F1){ref-type="fig"}) \[[@B8]\], a natural isoquinoline alkaloid present in roots, rhizome and outer bark of an important medicinal plant species, *Berberis (B. aquifolium, B. vulgaris, B. aristata*, etc.) has been reported to exhibit variety of pharmacological, biochemical and anticancer effects \[[@B9]\]. The medicinal value of berberine is indicated by its use in the Indian Ayurvedic, Unani and Chinese systems of Medicine since time immemorial \[[@B10],[@B11]\]. Berberine has been shown specifically to suppress the growth of a wide variety of tumors including leukemia \[[@B12]\], melanoma \[[@B13]\], epidermoid carcinoma \[[@B14]\], hepatoma \[[@B15]\], oral carcinoma \[[@B16]\] glioblastoma \[[@B17]\], lung \[[@B18]\], prostate \[[@B19]\] and gastric carcinoma \[[@B20]\] and does not have toxic effects on growth and viability of normal cells \[[@B14],[@B19],[@B21]\]. Animal studies have also shown that berberine can suppress chemical-induced carcinogenesis \[[@B22]\], tumor promotion \[[@B23]\] and tumor invasion \[[@B18],[@B24]\]. It also acts as a radiosensitizer of tumor cells but not for normal cells \[[@B25]\]. Though anticancer activity of berberine has been demonstrated \[[@B26]\] but how it mediate these effects is not clearly understood and also, its effect on HPV has not been reported. Therefore, in the present study, we have investigated the effect of berberine on HPV positive cervical cancer cells to examine its anti-viral activity. We show here that both viral transcription and cellular proliferation are strongly affected by berberine which specifically suppresses HPV transcription and constitutively active AP-1 in dose and time dependent manner.

![**The chemical structure of berberine**. Source: British booklet on Berberine \[[@B8]\].](1476-4598-10-39-1){#F1}

Materials and methods
=====================

Materials
---------

The HPV16 positive human cervical cancer cell line, SiHa, HPV18 positive human cervical cancer cell line, HeLa and the HPV negative human cervical cancer cell line, C33a were obtained from the American Type Culture Collection (ATCC), USA and were tested and authenticated prior to initiation of experiments and periodically checked for PCR positivity of HPV16 and HPV18 and contaminations to ensure purity of the cell line. DNA hybridization probes, pHPV16 represent unit-length of HPV16 DNA \[[@B2]\] cloned in pBR322, pHPV18 represent unit-length of HPV18 DNA \[[@B6]\] cloned in pBR322, and pHF-A \[[@B6]\] harboring an approximately full-length insert of the fibroblast β-actin gene was kindly provided by L. Kedes (Medical Center, Palo Alto, CA). Custom synthesized and HPLC purified Oligos were procured from M/s Microsynth, (Germany); Polyclonal antibodies to AP-1, hTERT, Caspase-3, Rb, PARP-1 and Monoclonal antibodies to HPV16E6/18E6, HPV16E7, HPV18E7, p53 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). DMEM, FCS, MTT, and Penicillin-Streptomycin solution were obtained from Sigma (St Louis, MO). All other reagents were of analytical molecular biology grades.

Cell culture
------------

Cells were maintained in Dulbecco\'s modified Eagle\'s medium (DMEM), supplemented with 10% heat- inactivated fetal calf serum and 1% penicillin/streptomycin in CO~2~incubator with a humidified atmosphere of 95% air and 5% CO~2~at 37°C.

Berberine
---------

Commercially available berberine (Sigma) was freshly dissolved in DMSO \[maximum concentration, 0.5% (v/v)\], which was then added to complete cell culture medium prior to addition to subconfluent cells. Cells treated with vehicle only (DMSO, 0.5% in media) served as control.

Lymphocytes isolation
---------------------

Peripheral blood lymphocytes were isolated from heparinized blood collected from healthy volunteers by standard method of Ficoll-Hypaque gradient centrifugation as described by Bharti et.al \[[@B27]\]. These cells were used for subsequent MTT assay.

MTT assay
---------

The cytotoxic effects of berberine against SiHa, HeLa, C33a and Lymphocytes were determined by MTT dye uptake method. The cells were incubated in triplicate in a 96-well plate in the presence or absence of indicated test samples in a final volume of 0.1 ml for 24 h, 48 h and 72 h at 37°C in a CO~2~incubator. Thereafter 0.025 ml of MTT solution (5 mg/ml in PBS) was added to each well. After 2 h incubation at 37°C, lysis buffer (20%SDS 50% Dimethyl Formamide) was added, and the extract was incubated overnight at 37°C for solublization of formazan crystals. The OD at 570 nm was measured using a 96-well multiscanner autoreader (Biotek, Winooski,Vermont) with the lysis buffer serving as blank. The percentage of cell viability was calculated using the following formula: Percentage cell viability = (OD of the experiment samples/OD of the control) × 100.

RNA Extraction and Northern blotting
------------------------------------

The cellular RNA were extracted following treatment of SiHa and HeLa cells with 0, 50, 100 and 250 μg/ml berberine for 24 h by using TRI Reagent according to the manufacturer\'s instruction. The quality of RNA was estimated by electrophoresis using 2 μl of RNA solution on an ethidium bromide-stained 1% agarose gel in 3-\[N-morpholino\] propane-sulfonic acid (MOPS) buffer. Concentration of RNA was estimated by Nanodrop (NanoDrop Tech, USA). The probes were labeled by the random-priming method using random primer labelling kit (Genei, Bangalore, India) and northern blotting was carried out using standard protocols \[[@B28]\]. Briefly, approximately 15 μg of RNA was resolved on 1% agarose- MOPS formaldehyde gel. Capillary blotted Nylon membrane (IMMOBILON-NY+, Millipore, Bedford, MA) was then UV crosslinked (Hoefer UVC 500 ultraviolet crosslinker, Amersham Biosciences) and washed in 6X SSC, air dried, and finally exposed in phosphorimager (Fujifilm FLA-5100) after pre-hybridization and hybridization in Perfect HYB-PLUS (Sigma Inc, USA) solution as suggested by manufacturer\'s protocol.

Electrophoretic mobility shift assay
------------------------------------

For electrophoretic mobility shift assay (EMSA), the following oligonucleotides were used: AP-1 consensus sequence 5\'-CGCTTGATGACTCAGCCGGAA-3\' \[[@B29]\], Oct-1 consensus oligonucleotide 5\'-TGTCGAATGCAAATCACTAGAA-3\'\[[@B30]\] and Sp-1 consensus sequence 5\'-ATTCGATCGGGGCGGGGCGAG-3\'\[[@B31]\]. Cells treated with different concentration of berberine for different time intervals were harvested and then nuclear extracts were prepared as described earlier \[[@B6]\]. The protein concentration of the extracts was measured by the spectrophotometric method using Nanodrop spectrophotometer ND-100. EMSA was performed using 10 μg of nuclear extract as described previously \[[@B6]\]. For supershift assays, 2 μg of polyclonal antibodies (Abs) directed against the Jun/Fos members (Santa Cruz Biotechnology Inc., Santa Cruz, CA) were added and the reaction mixture was further incubated for 45 mins at 4°C. The following antibodies were used: c-Jun (epitope corresponding to amino-terminal domain of mouse c-Jun p39); JunB (epitope corresponding to carboxy terminal domain of mouse JunB); JunD (epitope corresponding to carboxy terminus of mouse JunD); c-fos (epitope corresponding to a highly conserved domain of c-fos p62 of human origin); FosB (epitope corresponding to amino acids within the central domain of the FosB protein of mouse origin); Fra-1(epitope corresponding to amino terminus of Fra-1 of rat origin) and Fra-2 (epitope corresponding to carboxy terminus of Fra-2 of human origin). The DNA-protein complexes were then resolved on 4.5% nondenaturing polyacrylamide gel, dried and either exposed overnight to Kodak X-Omat Films (Kodak India Ltd., India) or visualized by PhosphorImager (Fujifilm FLA-5100) using Multi Gauge-ver 3.x anlaysis software. The quantitative densitometric analysis was performed using Alpha Ease FC version 4.1.0 (Alpha Innotech Corporation, IL).

Western blotting
----------------

Whole cell lysate (50 μg/lane) were resolved by SDS-PAGE, electrotransferred to Immobilon-P membranes (Millipore Corporation, Bedford, MA). The membrane was blocked with 10% non-fat milk and incubated overnight in PBS with 5% milk, 0.05% Tween-20 and probed with polyclonal rabbit primary antibodies of the corresponding family members (see Electrophoretic mobility shift assay for AP-1) at 4°C. These blots were washed, incubated with HRP- anti-rabbit IgG secondary antibodies and visualized by Luminol detection kit (Santa Cruz Biotech, USA). Membrane was re-probed for β-actin expression as an internal control. The ratio of the specific proteins to β-actin was calculated.

Flow cytometric analysis of apoptotic cell death by Annexin V-FITC
------------------------------------------------------------------

Cells were treated with berberine for 24 h. The cells were then harvested, washed with PBS and incubated with AnnexinV-conjugated fluorescein isothiocynate (FITC) and propidium iodide (PI) for cellular staining as described in AnnexinV-FITC apoptosis detection kit (BD Biosciences) manufacturer\'s instructions. The stained cells were then analyzed by FACS. The number of 10000 events was acquired and the cells were properly gated for analysis using FACSAria instrument equipped with Flowjo software (Becton-Dickinson Biosciences, San Jose, CA).

Quantitation of Caspase- 3 Activity
-----------------------------------

The activity of caspase-3 was measured using the active caspase-3 apoptosis kit (BD Pharmingen, USA) following the manufacturer\'s protocol. Briefly, cells were treated with different doses of berberine for 24 h or for different time intervals and were harvested by pooling attached and detached cells were pelleted with centrifugation at 200 × *g*for 5 min at 4°C. The cells were permeabilized, fixed, and stained for active caspase-3 (PE-conjugated) as described in manufacturer\'s protocol (BD Biosciences).

Measurement of mitochondrial membrane potential
-----------------------------------------------

Cells were plated onto a 60-mm tissue culture plate at subconfluent density. After 24 h incubation cells were exposed to different doses of berberine and incubated with 5 μM JC-1 fluorescence dye for 30 min in CO~2~incubator and washed several times with PBS pre-warmed at 37°C. Mitochondrial membrane potential was evaluated qualitatively under a fluorescence microscope (Olympus IX81) using 568 nm filter.

Statistical analysis
--------------------

All experiments were conducted in triplicate for at least three times. The statistical significance of difference between control and treated groups was analyzed by the one- way ANOVA (Holm-Sidak method) (Sigma Stat 3.5, Systat software Inc., CA). The difference was considered significant when the *p*value was less than 0.05.

Results
=======

Berberine selectively downregulates constitutively active AP-1 in HPV16 positive cervical cancer cells, SiHa
------------------------------------------------------------------------------------------------------------

To assess anti-HPV activity of berberine, we investigated the effect of berberine on AP-1, which is constitutively active in cervical cancer and plays an indispensable role in transcriptional regulation of HPV oncogenes. HPV16 positive cervical carcinoma cells, SiHa were treated with different concentrations of berberine for 24 h and the nuclear protein (10 μg) extracted were examined for AP-1 DNA-binding activity by EMSA. Results revealed a dose-dependent decrease of AP-1 DNA binding activity in berberine-treated cells (Figure [2A](#F2){ref-type="fig"}). Inhibition was apparent at 50 μg/ml and a maximum inhibition was obtained at 250 μg/ml. Densitometric analysis of the retarded bands showed a 10 fold decrease in AP-1 DNA-binding activity. Further analysis of time kinetics of berberine-induced AP-1 inhibition for different time periods revealed a reduced AP-1 DNA binding activity by 12 h which declined further and disappeared by 24 h (Figure [2B](#F2){ref-type="fig"}). Specificity of AP-1 DNA binding was confirmed by cold competition assay using 100 fold molar excess of a homologous (AP-1) probe which resulted in disappearance of retarded complex whereas it remained unaffected by addition of heterologous (Oct-1) probe (Figure [2C](#F2){ref-type="fig"}). Similarly, effect of berberine on general transcription was checked by examining nuclear protein (10 μg) of berberine-treated cells for binding to Sp1, a transcription factor that is ubiquitously active in majority of cells (Figure [2D](#F2){ref-type="fig"}). Results showed no inhibitory effect of berberine on Sp1 DNA binding activity. The results, thus establish that berberine selectively suppresses constitutively active AP-1 in a dose and time-dependent manner in cervical cancer cells.

![**Berberine specifically inhibits AP-1 DNA binding activity in HPV-16 positive cervical cancer cells**. SiHa cells treated with indicated concentrations of berberine for 24 h ***(A)***, or treated with 250 μg/ml berberine for indicated durations ***(B)***were assayed for AP-1 DNA binding activity by EMSA and fold change in DNA binding was calculated by densitometric evaluation of shifted band. ***C***, *Binding of AP-1 to its consensus oligo probe is specific*. Untreated SiHa nuclear proteins and labeled AP-1 probe were incubated in the presence of 100 fold molar excess of unlabeled homologous AP-1 probe or heterologous Oct-1 probe and assayed for AP-1 specific binding by EMSA. ***D***, *Berberine does not alter basal activity of other ubiquitous transcription factor Sp1*. Nuclear proteins (10 μg) of berberine- treated cells were checked for Sp1 DNA binding activity by EMSA. ***E***, *Effect of Berberine on composition of AP-1 in DNA-binding complex*. Nuclear proteins of berberine (250 μg/ml) treated cells for different time periods were checked for various AP-1 proteins present in functional AP-1 complex by supershift assay (\*Excess of nuclear proteins of 18 h treated cells were used to reveal participation of AP-1 members.) ***F***, *Effect of berberine on the expression of AP-1 family proteins*. Cellular proteins isolated from berberine (250 μg/ml) treated SiHa cells for indicated time durations were examined for the expression of AP-1 family proteins members. β-actin was used as loading control. The abundance ratio to β-actin was analyzed by densitometry. The data are expressed as the mean ± SD of 3 independent experiments.](1476-4598-10-39-2){#F2}

Berberine alters the heterodimerization pattern of AP-1 and differentially modulates expression of Jun and Fos family proteins
------------------------------------------------------------------------------------------------------------------------------

To determine the effect of berberine on composition of AP-1 complex and to dissect out the AP-1 protein most sensitive to berberine treatment, we performed supershift assays on SiHa nuclear proteins treated with berberine (250 μg/ml) for 8, 12 and 18 h. Under normal conditions, AP-1 consists of c-Fos, JunB, and JunD (Figure [2E](#F2){ref-type="fig"}) in its active DNA-binding complex and over 60% of the supershifted band was formed by c-Fos only, while other two members, JunB, and JunD, contributed moderately, but other Fos family members (FosB, Fra-1, Fra-2) as well as c-Jun did not participate in active AP-1 complex. Interestingly, nuclear protein extracted from berberine treated SiHa cells after 12 h displayed exclusive involvement of JunB in the binding activity (\~70%) with no involvement of either JunD/c-Jun or any of c-Fos family members in active AP-1 complex (Figure [2E](#F2){ref-type="fig"}). These results suggest that berberine-induced AP-1 inhibition is primarily mediated through exclusion of c-Fos family of proteins and JunD from active AP-1 complex whereas JunB DNA appears to form homodimer.

In order to assess the possibility of decreased involvement of c-Fos and JunD in active AP-1 complex could be due to their reduced expression, we analyzed expression of c-Fos, JunB, and JunD by western blotting at different time intervals following berberine treatment. As shown in Figure [2F](#F2){ref-type="fig"}, berberine-treated cells demonstrated reduced expression of c-Fos but interestingly though JunD also showed reduced expression by 12 h of treatment, its expression got recovered by 24 h. On the other hand, a compensatory and marginal increase in the expression of JunB was observed in berberine-treated cells. These results, therefore, indicate berberine-induced inhibition of AP-1 is primarily mediated through inhibition of c-Fos expression and its exclusion from active complex in cervical cancer cells.

Berberine inhibits AP-1 activity and reduces the expression of c-Jun and c-Fos in HPV18 positive cervical cancer cells
----------------------------------------------------------------------------------------------------------------------

We further looked into the effect of berberine on AP-1 activity in cervical cancer cells, HeLa that harbor HR-HPV18 infection and also express constitutively active AP-1. Nuclear proteins of HeLa cells which were treated with varying concentrations of berberine demonstrated a similar specific dose-dependent inhibition of AP-1 DNA binding by EMSA (Figure [3A, B](#F3){ref-type="fig"}). HeLa cell nuclear proteins were also examined for the composition of activated AP-1 complex by supershift assays revealed presence of c-Jun, JunB, JunD and c-Fos (Figure [3C](#F3){ref-type="fig"}) in active AP-1 complex whereas FosB, Fra-1,and Fra-2 showed no participation in the AP-1 complex formation. As compared to SiHa cells, where there is no involvement of c-Jun, we have found presence of c-Jun in HeLa cells but to a lesser extent. To determine the effect of berberine on specific AP-1 proteins involved in active complex, nuclear protein of HeLa cells treated with berberine were examined by supershift assays which displayed exclusive involvement of JunB and JunD in the binding activity with no involvement of c-Fos (Figure [3C](#F3){ref-type="fig"}). These results suggest that c-Fos is the most sensitive AP-1 member and its exclusion from active AP-1 complex contributes maximally to the loss of AP-1 activity in berberine-treated cells. Further investigation of AP-1 protein expression revealed a dose-dependent loss of c-Fos and c-Jun in berberine treated cell (Figure [3D](#F3){ref-type="fig"}). These observations collectively indicated exclusion of Fos member from active complex and loss of AP-1 activity are primarily mediated through loss of expression of c-Fos and c-Jun in berberine-treated cells.

![**Berberine specifically downregulates constitutive active AP-1 in HPV18 positive cervical cancer cells**. ***A***, *Dose-dependent downregulation of AP-1 binding activity*. Nuclear proteins of HeLa cells treated without or with indicated concentrations of berberine for 24 h were prepared and assayed for AP-1 DNA binding activity by EMSA. As indicated in \"Methods\" fold change was calculated following densitometric evaluation of shifted band. ***B***, *Binding of AP-1 to its consensus oligo probe is specific*. Binding specificity of AP-1 to its consensus probe was examined by cold competition in a binding reaction of untreated HeLa nuclear proteins and labeled AP-1 probe adding 100 fold molar excess of unlabeled homologous AP-1 probe or heterologous Oct-1 probe. ***C***, *Berberine changes composition of AP-1 DNA-binding complex in HeLa cells*. Equal amount of nuclear extracts (10 μg/lane) isolated from untreated as well as treated (100 μg/ml berberine for 18 h) HeLa cells were checked for binding partners in functional AP-1 complex by co-incubating these extracts individually with different antibodies as described in \'Methods\'. (\*Excess of nuclear proteins used to reveal participation of AP-1 members.) ***D***, *Effect of berberine on the expression of AP-1 family proteins*. HeLa cells treated with berberine for indicated doses and protein isolated from these cells were subjected to western blot analysis as described in \"Methods\". β-actin was used as loading control. The abundance ratio to β-actin was analyzed by densitometry. The data are expressed as the mean ± SD of 3 independent experiments.](1476-4598-10-39-3){#F3}

Berberine downregulates HPV16 and HPV18 transcription, suppressed E6, E7 and hTERT expression and increased p53 and Rb expression in cervical cancer cells
----------------------------------------------------------------------------------------------------------------------------------------------------------

To investigate, whether inhibition of AP-1 by berberine has any impact on the viral transcription, total RNA was extracted from the SiHa and HeLa cells following treatment with different concentrations of berberine for 24 h and northern blotting was performed using HPV16-DNA and HPV18-DNA probes respectively. The results revealed a concentration dependent decline in HPV16-specific transcripts in berberine-treated SiHa cells (Figure [4A](#F4){ref-type="fig"}). Berberine at 50 μg/ml was found to significantly downregulate viral transcription and strongest reduction was detected in cells treated with 250 μg/ml. A decline in HPV18-specific transcripts was also observed in berberine-treated HeLa cells (Figure [4A](#F4){ref-type="fig"}). Suppression of HPV transcription was found to be selective since expression of house keeping gene, β-actin was not affected in both the cells.

![**Berberine downregulates HPV oncogene expression, increased p53, Rb levels and inhibit hTERT expression in cervical cancer cells**. ***A***, *Effect of berberine on HPV16 and HPV18 mRNA expression*. Northern blots (middle panels) of HPV16 positive SiHa cells and HPV18 positive HeLa cells incubated with indicated concentrations of berberine. Quantity and quality of total RNA (15 μg/lane) extracted was examined on agarose gel (upper panels). The membrane was rehybridized with β-actin-specific DNA probe as internal control to assess equal loading (lower panels). ***B***, *Effect of berberine on the expression of HPV E6 and E7 oncoproteins*. Representative immunoblots of HPV16E6 &E7 and HPV18E6 &E7 in SiHa and HeLa cells respectively treated with berberine for indicated doses. β-actin was used as loading control. ***C***, *Effect of berberine on the expression of p53 and Rb proteins*. HPV16 positive SiHa cells and HPV18-positive HeLa cells were treated with different concentration of berberine. The cells were harvested after 24 h to obtain whole cell extracts, which were analyzed for p53 and Rb expression by Western blotting. Equal sample loading was confirmed by determining the β-actin expression levels. ***D***, *Effect of berberine on the expression of hTERT*. Immunoblots of cellular proteins isolated from SiHa and HeLa cells treated with berberine. β-actin was used as loading control. The abundance ratios to β-actin were analyzed by densitometry. The data are expressed as the mean ± SD of 3 independent experiments.](1476-4598-10-39-4){#F4}

We then proceeded to investigate the expression level of HPV oncogenes, E6 and E7 after berberine treatment. Data from western blotting analysis showed that the expression of HPV16E6, HPV16E7, HPV18E6 and HPV18E7 were significantly suppressed by berberine in cervical cancer cells in a dose-dependent manner (Figure [4B](#F4){ref-type="fig"}).

The two most essential cell cycle regulators and tumor suppressor proteins, p53 and Rb being the targets of high-risk HPV E6 and E7 oncoproteins respectively, we also examined the status of p53 and Rb expression in SiHa and HeLa cells. Both of these cervical cancer cells expressed p53 and Rb at low levels which showed a dose- dependent increase in expression following treatment with berberine (Figure [4C](#F4){ref-type="fig"}).

Since two viral oncoproteins, E6 and E7 encoded by HR-HPVs contribute to immortalization of primary human epithelial cells through the induction of telomerase activity by stimulating transcription of the catalytic subunit of telomerase, hTERT, we examined whether suppression of HPV transcription and reduced expression of viral oncogenes due to berberine also result in altered expression of hTERT. Cellular proteins (50 μg) extracted from SiHa and HeLa cells were incubated in the absence or presence of berberine (100 μg/ml for 24 h) was checked for hTERT expression using western blotting. As depicted in Figure [4D](#F4){ref-type="fig"}, high expression of hTERT protein was observed in untreated cells which decreased significantly upon berberine treatment in both the cells.

Berberine decreases cell viability and induce growth inhibition in cervical cancer cells
----------------------------------------------------------------------------------------

Activation of AP-1 along with increased expression of viral oncoproteins and telomerase are all critical prerequisites for growth promoting and cell survival mechanisms of cervical cancer cells. Therefore, we were interested to check how does inhibition of these factors translates onto cell survival and growth of berberine-treated cells. For this, cells were treated with different concentration of berberine for 24 h and their viability was checked by MTT assay. As indicated in Figure [5A](#F5){ref-type="fig"}, Treatment of berberine with varying concentration resulted in concentration-dependent loss of cell viability of both SiHa and HeLa cells with 50% inhibitory dose (ID~50~) of approximately 90 μg/ml for SiHa and 75 μg/ml for HeLa cells and maximal effect was observed at 250 μg/ml. SiHa cells were also checked for their growth kinetics at 24, 48 and 72 h in the absence or presence of different concentration of berberine. As summarized in SiHa cell growth curves in the presence of berberine (Figure [5B](#F5){ref-type="fig"}), berberine at as low as 10 μg/ml could retard the growth of cervical cancer cells. Berberine at concentration higher than 50 μg/ml resulted in reduced cell viability drastically and cultures did not recover within 72 h. Though berberine inhibits cell proliferation of HPV positive cervical cancer cells, however, in case of HPV negative cervical cancer C33a cells we did not find significant inhibitory effect of berberine on cell viability (1-24% inhibition) (Figure [5A](#F5){ref-type="fig"}). Treatment of lymphocytes with berberine also results in a non significant inhibitory effect on cell viability (1-4%) at the higher concentrations of berberine (100 μg/ml and 250 μg/ml) after 24 h of treatment (Figure [5A](#F5){ref-type="fig"}). These data indicates that berberine has a better cytotoxic effect on HPV positive human cervical cancer cells.

![**Berberine treatment results in dose-dependent loss of cell viability and induces growth inhibition in cervical cancer cells**. ***A***, *Percent cell viability of cells treated with berberine for 24 h*. Cervical cancer cells and normal peripheral blood lymphocytes were treated with indicated doses of berberine in triplicates and the viability was measured at different time intervals by MTT assay as described in \"Methods\". ***B***, *Growth curve of berberine-treated SiHa cells at different time points reflecting cytotoxic and cytostatic effects at different concentration*. Error bars indicates SD. ^a^*p*- \< 0.001 is compared to untreated control at 24 h, ^b^*p*- \< 0.001 is compared to untreated control at 48 h, ^c^*p*- \< 0.001 is compared to untreated control at 72 h.](1476-4598-10-39-5){#F5}

Berberine-induced growth inhibition is mediated through induction of apoptosis
------------------------------------------------------------------------------

To understand the mechanism of berberine-induced growth inhibition and to examine whether berberine-induced inhibition of cervical cancer cells was associated with the induction of apoptosis, SiHa and HeLa cells were treated with berberine and berberine-induced apoptosis was assessed using Annexin V-PI staining of the treated cells that identify specifically the cells undergoing apoptotic cell death and start expressing phosphatidylserine on their cell surface. As shown in Figure [6A](#F6){ref-type="fig"}, cells treated with berberine had a very high Annexin V staining and were also positive for PI, a phenotype generally expressed by early apoptotic cells when compared to untreated cells.

![**Berberine induces apoptosis, activation of Caspase 3 and loss of mitochondrial membrane potential in cervical cancer cells**. ***A***, *Flowcytometric analysis of SiHa and HeLa cells treated with berberine for 24 h*. Treated cells were examined for apoptotic cells using Annexin V-FITC apoptosis detection kit. ***B***, Immunoblot analysis of cellular protein isolated from SiHa and HeLa cells treated with berberine for PARP-1 expression as described in \"Methods\". ***C***, *Flowcytometric analysis of SiHa and HeLa cells for active caspase-3*. Percentage in histograms shows proportion of cell with active caspase-3 after berberine treatment. ***D***, *Immunofluorescence photomicrograph of JC-1 stained untreated, control (DMSO only) and berberine treated SiHa and HeLa cells*. Cells appearing in red channel indicate intact mitochondrial transmembrane potential, whereas cells appearing in green channel indicate loss of mitochondrial membrane potential.](1476-4598-10-39-6){#F6}

To further dissect the berberine-induced apoptotic mechanism, we checked the effect of berberine on Poly (ADP-ribose) polymerase (PARP-1) cleavage, the downstream substrate of active caspase 3. Berberine-treated whole cell lysates (50 μg) of SiHa and HeLa cells were probed for the analysis of PARP-1 by western blotting which showed cleavage of 116 kDa intact PARP-1 into 85 kDa fragment in both the cells (Figure [6B](#F6){ref-type="fig"}). The quantitation of cells for active caspase 3 by flow cytometry revealed 70% cells positive by 24 h when treated with 100 μg/ml berberine and almost all cells had active caspase-3 when treated with 250 μg/ml of berberine in SiHa cells (Figure [6C](#F6){ref-type="fig"}). About 99% cells were positive for active caspase-3 in HeLa cells treated with 100 μg/ml berberine for 24 h (Figure [6C](#F6){ref-type="fig"}).

Since loss of mitochondrial membrane potential is the primary target for majority of extrinsic apoptotic signals, we checked the integrity of mitochondrial membrane using metachromatic dye, 5,5\'6,6\' tetrachloro-1,1\'3,3\' tetraethylbenzimidazolylc iodide (JC-1), which stains the mitochondria red when their membranes are intact (polarized) whereas they give green fluorescence with depolarized membranes. Figure [6D](#F6){ref-type="fig"} clearly demonstrates that in cells treated with a high concentration of berberine (Figure [6D](#F6){ref-type="fig"}, *bottom panels*) mitochondria lost their membrane potential and thus proceeded through apoptosis.

Discussion
==========

Host cell derived transcription factor, AP-1 binds to long control region or upstream regulatory region (URR) of HPV, plays an essential role in HPV-mediated host cell immortalization and oncogenic transformation. Site- directed mutagenesis of AP-1 binding sites within the URR regions \[[@B32]\] and stable infection assays in raft culture \[[@B33]\] have established an indispensible role of AP-1 in initiating and maintaining the expression of two essential high risk HPV oncoproteins E6 and E7 during cervical carcinogenesis. Earlier studies from our group and others have demonstrated overexpression and constitutive activation of AP-1 in cervical cancer cells and the DNA binding affinity of AP-1, as well as the expression of its constituent members, varies as a function of the severity of cervical lesions \[[@B6],[@B34]\]. Thus transcription factor, AP-1 can be considered as potential therapeutic targets for cervical cancer. In the present investigation, we show that a naturally occurring isoquinoline alkaloid, berberine, selectively suppress expression of AP-1 transcription factor in a dose and time dependent manner. Inhibition of AP-1 was accompanied by suppression of HPV transcription and oncogene expression as well as inhibition of downstream telomerase component, hTERT. Berberine-mediated inhibition of growth promoting signals culminated in growth inhibition and loss of cell viability through induction of apoptosis in cervical cancer cells. Our results demonstrated a dose-dependent selective suppression of AP-1 activity by berberine which was accompanied by suppression of c-Fos and JunD expression and their reduced involvement in functional AP-1 complex in HPV positive cervical cancer cells irrespective of infecting HR-HPV types whereas JunB that also participated in an active AP-1 complex remained unaffected. Comparison between the two cell lines revealed a specific effect of berberine on c-Fos and c-Jun resulting in their exclusion from the functional AP-1 complex which could be partly due to downregulation of their respective expression levels. Earlier studies also described berberine-induced inhibition of AP-1 in murine tumor models as well as hepatic, breast and oral cancer cells \[[@B16],[@B24],[@B35]\], but the mechanism of its inhibition remained unclear. Recent study shows that inhibitory effect of berberine could be mediated through inhibition of c-Jun that suppresses expression of downstream gene, cyclin D1 and results in cell cycle arrest \[[@B36]\]. However, in HPV16 positive SiHa cells or HPV18 positive HeLa cells it appears that berberine is not executing its effect through this mechanism as involvement of c-Jun in active AP-1 is negligible \[[@B6]\]. On the contrary, expression of c-Fos which is the major partner of active AP-1 dimer was the target of berberine and was found to be the most sensitive among all AP-1 proteins. Although further experiments using selective inhibition of c-fos and JunD by specific siRNA or reporter assays comparing the different homodimers and heterodimers of Jun and Fos family members are required to validate the significance of altered AP-1 composition, the present observations do support berberine as a preferred anti-HPV therapeutic molecule for cervical carcinogenesis. Rapidly growing amount of data from experimental, clinical and animal studies reveal that c-Fos appears to have strong oncogenic activity and is frequently overexpressed in almost all tumor cells \[[@B5]\]. Our earlier study demonstrated c-Fos as a major AP-1 member which showed high expression in cervical carcinogenesis \[[@B6]\]. In an ingenious experiment where c-Fos was ectopically over expressed through stable transfection of nontumorigenic HeLa-fibroblast hybrid 444 cells, it induced tumorigenity. This reiterates the tumorigenic role of c-Fos \[[@B37]\]. AP-1 has been shown to be an important target for anti-oxidant mediated action on cervical cancer cells \[[@B28]\]. However, the mechanism of their action may differ as antioxidants like PDTC enhances AP-1 binding and elicits up-regulation of c-Fos and c-Jun expression. Instead of acting directly on c-Fos it results in upregulation of Fra-1 which has antagonistic role to c-Fos and prevents its involvement in formation of functional AP-1 complex \[[@B28]\]. Though the mechanism(s) underlying berberine-induced inhibition of c-Fos expression is unclear, studies on vascular smooth muscle cells demonstrated that berberine can inhibit c-Fos expression by inhibiting ERK1/2 \[[@B38],[@B39]\], the upstream kinases responsible for c-Fos expression through transcription factor TCF/Elk-1 \[[@B40]\].

The gradual but distinct increase in JunB protein expression after berberine treatment strongly support the tumor suppressor activity of JunB as it was earlier reported that JunB and JunD can negatively regulate cell proliferation \[[@B41]\] and has an opposite effect on gene expression. Furthermore, JunB is also known to be a weaker transactivator than c-Jun \[[@B42]\]. Though JunB is essential for the HPV18 P105 promoter activation \[[@B32]\], there may be possibility that interaction with other proteins may inhibit DNA binding due to direct protein-protein interaction \[[@B43]\] thus, negative interference between proteins, either c-Jun or JunD may be one of the reasons of decrease in AP-1 DNA binding activity.

Our results indicate that berberine can effectively suppress HPV transcription and thus could inhibit the expression of its two oncogenes, E6 and E7 that are critically involved in cellular transformation. Spatial and temporal expression of these viral genes is tightly controlled by specific cognate sequences in URR that bind specific transcription factors of the host cells. The sequence analysis of viral URR region which controls the expression of these oncogenes demonstrates presence of multiple AP-1 binding sites \[[@B44]\] and thus indicates a direct involvement of this transcription factor in oncogenic transformation. Suppression of HPV transcription by berberine, therefore, could be the direct outcome of inhibited AP-1 activation in cervical cancer cells. Apart from targeting p53 and pRB, E6 and E7 have been demonstrated to induce transcription of hTERT, the active component of telomerase responsible for its catalytic activity \[[@B45]\]. Berberine-induced inhibition of viral transcription was associated with suppressed hTERT expression; hence berberine could also target telomerase activity in cervical cancer cells, which we have shown earlier to be an important marker for cervical carcinogenesis \[[@B46]\]. Earlier study on human leukemia cells also provided the evidence that berberine could inhibit telomerase by directly inhibiting expression of its components nucleophosmin/B23 \[[@B47]\] and thus could effectively suppress overall activity independent of HPV involvement. Collectively these observations indicate that berberine could effectively target survival advantage rendered by telomerase expression in HPV-infected cervical cancer cells and could suppress cell proliferation.

In addition to its inhibitory effects on HPV transcription, berberine also antagonizes cell proliferation. Our results demonstrate two distinct concentration-dependent growth inhibitory effects of berberine on cervical cancer cells. Berberine at 50 μg/ml or lower suppressed proliferation whereas at concentration higher than 50 μg/ml resulted in dose-dependent apoptosis. Similar concentration-dependent biphasic effects have been reported earlier \[[@B48]\]. Similar to the cytotoxic/cytostatic effect of berberine observed in present investigation especially in cancer cell lines in contrast to normal lymphocytes, a comparative analysis of studies performed on various human cancer cell lines and primary cultures using purified berberine revealed a differential sensitivity of various cancer cell types whereas normal cells remained unaffected (Table [1](#T1){ref-type="table"}). Interestingly, majority of studies performed on cervical cancer cells showed requirement of high concentration of berberine for manifestation of its cytotoxic effect \[[@B26],[@B49],[@B50]\] which could be ascribed to viral etiology of cervical cancer and overexpression of viral oncoproteins E6 and E7 that may effectively override cellular checkpoints. However, it was also observed that the effective cytotoxic doses were always less in HPV positive cells as compared to HPV negative cervical cancer cell, C33a that have undergone cellular transformation independent of viral infection. The reason for such a dichotomy in berberine\'s effect in cervical cancer cells is unclear.

###### 

Comparative analysis of *in vitro*studies performed for assessing anti-cancer properties of purified berberine (\>99%) in various human cancer and normal cells

  Cells Type (Human)                  Cell Line                           Concentration Range Tested   Percent Cell Death at max. Dose after 24 h (Approx; %)   **IC**~**50**~**(μg/ml) after 24 h**   References      
  ----------------------------------- ----------------------------------- ---------------------------- -------------------------------------------------------- -------------------------------------- --------------- -------------------
  **Tongue squamous carcinoma**       **SCC-4**                           15 - 100                     5.58 - 37                                                45                                     28 (48 h)       \[[@B55]\]
  **Prostrate carcinoma**             **LNCaP**                           10 - 100                     3.7 - 37                                                 35                                     \>37            \[[@B19]\]
                                                                          5 - 100                      1.8 - 37                                                 65                                     22.3            \[[@B56]\]
                                      **DU145**                           10 - 100                     3.7 - 37                                                 40                                     \>37            \[[@B19]\]
                                      **PC-3**                            10- 100                      3.7 - 37                                                 70                                     18.6            \[[@B19]\]
                                                                          5 - 100                      1.8 - 37                                                 50                                     37              \[[@B56]\]
  **Oral squamous cell carcinoma**    **HSC-3**                           5 - 75                       1.8 - 28                                                 82                                     6.7             \[[@B57]\]
  **Non-small cell lung carcinoma**   **A549**                            25 - 100                     9.3 - 37                                                 55                                     28              \[[@B21]\]
                                      **H1299**                           25 - 100                     9.3 - 37                                                 50 (48 h)                              37 (48 h)       \[[@B21]\]
  **Nasopharyngeal carcinoma**        **5-8F**                            2.5 - 100                    0.93 - 37                                                50                                     37              \[[@B58]\]
  **Leukemia**                        **HL-60**                           5 - 60                       1.8 -22                                                  70                                     \<11            \[[@B59]\]
  **Hepatoma**                        **KIM-1**                           0.01 - 100                   0.0037 - 37                                              35                                     14.88           \[[@B35]\]
                                      **Hep3B**                           0.32- 320                    0.119 - 119                                              8.5                                    Not defined     \[[@B60]\]
                                      **HA22T/VGH**                       0.32 - 320                   0.119 - 119                                              1                                      Not defined     \[[@B60]\]
                                      **HepG2**                           28 - 107                     10 - 40                                                  95                                     13 (48 h)       \[[@B61]\]
                                                                          1 - 10                       0.37 - 3.7                                               70                                     0.52            \[[@B62]\]
                                                                          0.32 - 320                   0.119 - 119                                              6                                      ND              \[[@B60]\]
  **Glioma**                          **U87**                             1 -20                        1 - 7.4                                                  40                                     \>7.4           \[[@B63]\]
                                      **T98G**                            134 - 538                    50 - 200                                                 60                                     134             \[[@B17]\]
  **Gastric carcinoma**               **SNU-5**                           50 - 200                     18.6 - 74                                                95                                     17.85           \[[@B20]\]
  **Embryonic kidney**                **HEK-293T**                        1 - 10                       0.37 - 3.7                                               35                                     5               \[[@B62]\]
  **Epidermoid carcinoma**            **A431**                            5 - 75                       1.8 - 28                                                 45                                     \>28            \[[@B14]\]
  **Breast carcinoma**                **MDA-MB-231**                      1 - 10                       1 - 3.7                                                  0                                      Not defined     \[[@B24]\]
  **Cervical carcinoma**              **C33a (HPV-)**                     **2.7 - 672**                **1 - 250**                                              **24**                                 **\>250**       **Current study**
                                      **CaSki (HPV16+)**                  50 - 150                     18.6 - 55.8                                              80                                     42              \[[@B26]\]
                                      **SiHa (HPV16+)**                   **2.7 - 672**                **1 - 250**                                              **87**                                 **90**          **Current study**
                                      **HeLa (HPV18+)**                   0.27 - 403                   0.1 - 150                                                ND                                     6               \[[@B49]\]
                                                                          0.1 - 10                     0.037 - 3.7                                              No effect                              Not defined     \[[@B64]\]
                                                                          33.5 - 269                   12.5 - 100                                               50                                     100             \[[@B50]\]
                                                                          1 - 10                       0.37 - 3.7                                               48                                     4               \[[@B62]\]
                                                                          **2.7 - 672**                **1 - 250**                                              **90**                                 **75**          **Current study**
  **Normal Cells**                    **Bronchial epithelium**            25 - 100                     9.3 - 37                                                 5                                      No effect       \[[@B21]\]
                                      **Lymphocytes**                     **2.7 - 672**                **1 - 250**                                              **4**                                  **No effect**   **Current study**
                                      **Prostrate epithelium (PWR-1E)**   5 - 100                      1.8 - 37                                                 40                                     Not defined     \[[@B56]\]
                                                                          10 - 100                     3.7 - 37                                                 5                                      No effect       \[[@B19]\]
                                      **Epidermal keratinocytes**         5 - 75                       1.8 - 28                                                 11 (48 h)                              No effect       \[[@B14]\]

The anti-proliferative and apoptotic activity of berberine have been attributed to its concentration-dependent selective accumulation in mitochondria at lower concentration and nuclear as well as cytoplasmic accumulation at higher mitochondria-saturating doses that could interfere with DNA synthesis, perturb cell cycle and sufficient to trigger apoptosis. Our long term cultures of berberine-treated cells also demonstrated a suppressed growth at low doses without any prominent cell death component. Since berberine is a substrate of ATP-driven drug efflux pump \[[@B51]\], it is likely that at saturating concentrations berberine reduces the energy levels of the mitochondria below critical levels resulting in triggering of programmed cell death. This assumption gets strength from the experiments showing berberine effectively synergizes with drug efflux pump inhibitors \[[@B52]\]. Some investigators propose berberine\'s DNA-binding activity\[[@B53]\] could be responsible for rapid inhibition of DNA synthesis of berberine-treated cells and cell cycle arrest in S phase and G2/M phase \[[@B20]\]. Apart from these direct actions of berberine its inhibitory action on viral oncoproteins (E6/E7) expression via inhibition of AP-1 could be primarily responsible for growth suppression and induction of apoptosis in HPV positive cervical cancer cells. Our observations together with confirmatory annexin V analysis, suggest berberine could antagonize multiple survival and growth promoting mechanisms operating in cervical cancer cells and can induce apoptosis in a dose-dependent manner.

The key biochemical event involved in the induction of apoptosis is activation of caspase3 which is mediated through proteolytic cleavage of procaspase3 via upstream caspases (caspase7/9 or caspase 8). Berberine-treated cells demonstrated activation of caspase3 which also corroborated with proteolytic cleavage of its substrate PARP-1 as early as 6 hours. These apoptotic events were found associated with loss of mitochondrial membrane potential which is the primary mechanism of action of many chemotherapeutic/chemopreventive agents as well as other external apoptotic stimuli \[[@B54]\]. This event is sufficient to release cytochrome C from mitochondrial membrane and execute proteolytic activation of caspases. Nonetheless, direct mitochondrial tropism of berberine through induction of GADD153 levels \[[@B26]\] could also have directly contributed to the loss of mitochondrial potential. Though there could be multiple direct or indirect mechanisms, these observations collectively indicate a potential role of mitochondria in berberine-induced apoptosis.

Conclusions
===========

In view of potential anti-HPV activity displayed by berberine through inhibition of constitutively active AP-1 as well as its selective, anti-proliferation and cytotoxic effects coupled with pharmacological safety in human, berberine appears to be a promising therapeutic agent for the treatment of cervical cancers.
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HPV: Human Papillomavirus; AP-1: Activator protein-1; EMSA: electrophoretic mobility shift assay; PARP-1: Poly (ADP-ribose) - polymerase-1; MTT: 3-(4, 5-dimethylthiazol-2-yl)-2; 5-diphenyltetrazolium bromide; FACS: fluorescence-activated cell sorting.
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